Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:New York, NY
Treatments:Chemotherapy, Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Oct 2009

Description:

Patients:
This study involved 36 men with metastatic castration-resistant prostate cancer. The median age was 66 years old, with a range of 52-84 years.

Treatment:
Patients were administered a combination of the biologic therapy cetuximab, which is a monoclonal antibody that targets cancer cells to be killed by the immune system, and the chemotherapeutic agent doxorubicin.

Toxicity:
Maximum toxicity observed in this study was of grade 3 and included nausea, fever, and vomiting. The most common complications were grade 1 fatigue (46% of patients) and grade 2 stomatitis (43%).

Results:
Median overall survival for this study was 18 months.

Support:
This study was supported by ImClone Systems, Inc., the makers of cetuximab (trade name Erbitux)

Correspondence: Dr. Susan F. Slovin; e-mail: [email protected]



Back